Put companies on watchlist
Cantourage Group SE
ISIN: DE000A3DSV01
WKN: A3DSV0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cantourage Group SE · ISIN: DE000A3DSV01 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 2067531
15 January 2025 07:30AM

Cantourage Group SE increases its sales by 118% to EUR 51.4 million in full year 2024


EQS-News: Cantourage Group SE / Key word(s): Development of Sales
Legalization of cannabis brings strong growth: Cantourage Group SE increases its sales by 118% to EUR 51.4 million in full year 2024

15.01.2025 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.
 

Legalization of cannabis brings strong growth: Cantourage Group SE increases its sales by 118% to EUR 51.4 million in full year 2024

Berlin, January 15, 2025 – Cantourage Group SE (hereafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading publicly listed cannabis company, posted sales of EUR 51.4 million in the full year 2024. This exceeded the most recently raised sales forecast for 2024 (EUR 46 million to EUR 50 million). The growth in sales in 2024 represents an increase of 118% compared to the previous year (2023: EUR 23.6 million) and demonstrates the exceptional scalability and performance of Cantourage’s business model.

On a monthly and quarterly basis, Cantourage continued to see strong growth in sales throughout 2024. At the end of the year, Cantourage once again set new sales records at both the monthly and quarterly level:

  • Sales in December 2024: EUR 8.5 million (previous record: EUR 7.2 million; November 2024)
  • Sales in Q4 2024: EUR 21.2 million (previous record: EUR 13.2 million; Q3 2024)

The main driver of this positive business performance was the continuously growing demand for Cantourage’s cannabis flowers, especially in Germany and the UK. By significantly expanding its own processing capacities, the company was increasingly able to meet the sustained increase in demand for cannabis-based pharmaceuticals in its various markets over the course of 2024.

“2024 was a very eventful year for cannabis in Germany. Over the course of the year, it became clear that the partial legalization in April is giving more and more people access to medical cannabis – and bringing enormous economic potential for the entire industry. We are pleased to be able to meet the growing demand for high-quality, safe cannabis flowers together with our strong partner network. Despite all the macroeconomic challenges, we have now exceeded the EUR 50 million sales mark only five and a half years after our company was founded. We have thus increased our sales revenues of around EUR 500,000 in 2020, when we launched our first product, by more than a hundredfold,” said Philip Schetter, CEO of Cantourage.

“For 2025, we have already launched new growth drivers such as our recent very successful market entry in Poland or the relaunch of our telemedicine platform www.telecan.de,” emphasizes Philip Schetter. “By doing so, we want to support even more people on their way to cannabis therapy and expand our leading position in the dynamic European market environment – while continuing to grow profitably as a company. With the help of our asset-light business model, we will be able to realize this growth using our own resources. Overall, we will place a strong emphasis on continuously improving our efficiency, making even better use of economies of scale and significantly increasing our profitability even further.”
 

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com
 

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
 

Press contact at Cantourage:

Frederick Steudemann
Tel. +49 (0)30 4701 350 - 50
steudemann@cantourage.com

 

 



15.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2067531

 
End of News EQS News Service

2067531  15.01.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2067531&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Cantourage Group SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.